Friday - March 29, 2024
Baylor College of Medicine: Trial Results Show Potential Benefits of Tocilizumab for COVID-19
February 26, 2021
HOUSTON, Texas, Feb. 26 (TNSJou) -- The Baylor College of Medicine issued the following news release:

Tocilizumab (TCZ) is one of multiple drugs that have been studied in clinical trials around the world as a potential treatment for COVID-19. A team of international researchers present their results from the COVACTA trial in the New England Journal of Medicine (NEJM).

Baylor College of Medicine was one of the research sites for COVACTA, which evaluated the therapeutic b . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products